Patel Shalin S, Schwab Joseph H
Department of Orthopaedic Surgery, Massachusetts General Hospital Harvard Medical School, 55 Fruit Street Yawkey Building Suite 3A, Boston, MA, 02114-2696, USA.
Curr Oncol Rep. 2016 Sep;18(9):55. doi: 10.1007/s11912-016-0543-8.
Chordoma is a locally aggressive primary malignancy of the axial skeleton. The gold standard for treatment is en bloc resection, with some centers now advocating for the use of radiation to help mitigate the risk of recurrence. Local recurrence is common, and salvaging local failures is quite difficult. Chemotherapy has been ineffective and small molecule targeted therapy has had only marginal benefits in small subsets of patients with rare tumor phenotypes or refractory disease. Recent successes utilizing immunotherapy in a variety of cancers has led to a resurgence of interest in modifying the host immune system to develop new ways to treat tumors. This review will discuss these studies and will highlight the early studies employing immune strategies for the treatment of chordoma.
脊索瘤是一种发生于中轴骨骼的局部侵袭性原发性恶性肿瘤。治疗的金标准是整块切除，现在一些中心主张使用放疗来降低复发风险。局部复发很常见，挽救局部复发的情况非常困难。化疗一直无效，小分子靶向治疗仅在少数具有罕见肿瘤表型或难治性疾病的患者亚组中带来了些许益处。最近在多种癌症中使用免疫疗法取得的成功，引发了人们对调节宿主免疫系统以开发治疗肿瘤新方法的兴趣再度高涨。本综述将讨论这些研究，并重点介绍采用免疫策略治疗脊索瘤的早期研究。
